Aug. 28 at 2:11 AM
LifeVantage reported fiscal Q4 and full-year 2026 results after the market close, triggering a sharp negative reaction from investors. The company entered the report with already weakened fundamentals after several quarters of declining performance.
In fiscal Q3 2026, revenue fell 25.2% YoY to
$43.7 million, while diluted EPS dropped to
$0.11 from
$0.26 a year earlier. Revenue missed analyst estimates by 8.5%, while EPS came in 35% below expectations. Institutional sentiment also deteriorated, with 68 investors reducing their positions versus 39 increasing them. BlackRock cut its stake by 65.1%, selling more than 501,000 shares, while Geode Capital Management reduced its position by 53.7%.
The broader market provided little support, with the S&P 500 down 0.1% and the Nasdaq off 0.2%. Analysts expect LifeVantage revenue to decline an average of 5.4% annually over the next three years, contrasting with projected 3.7% annual growth for the broader U.S. personal-care products industry
$LFVN